ORIGINAL ARTICLE

CD14 and CD16 expression in noninfectious granulomatous skin diseases

Yuta Ito MD | Maki Kitakawa MD | Sachiko Koshikawa | Hideaki Watanabe MD | Hirohiko Sueki MD 🕩

Department of Dermatology, Showa University School of Medicine, Tokyo, Japan

Correspondence

Hirohiko Sueki, Department of Dermatology, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.

Email: hirsueki@med.showa-u.ac.jp

Abstract

Objectives: Peripheral blood monocytes are categorized as classical (CD14⁺⁺/CD16⁻) or nonclassical (CD14⁻/CD16⁺ and CD14⁺/CD16⁺) based on their CD14 expression and CD16 expression. Maturation of classical monocytes produces CD14⁺/CD16⁺ macrophages. Our aim was to clarify the in vivo distribution of CD14 and C16 monocytes/macrophages in three granulomatous skin diseases-sarcoidosis, granuloma annulare, and lupus miliaris disseminatus faciei.

Methods: CD14 and CD16 immunohistochemistry, and CD14/CD16, CD16/CD11c, CD16/CD68, and CD16/factor XIIIa dual labeling were performed in tissues sampled from three cases of sarcoidosis, four cases of granuloma annulare, and three cases of lupus miliaris disseminatus faciei.

Results: The main infiltrating cell types were CD14⁺/CD16⁺ and CD14⁻/CD16⁺⁺ macrophages. A small number of CD14⁺/CD16⁻ macrophages localized along the granuloma periphery. Dual immunofluorescence showed that CD16⁺ overlapped the most with CD68⁺ cells, partially overlapped with CD11c⁺ cells, and did not overlap with $FXIIIa^+$ cells.

Conclusions: Inflammatory granulomatous skin diseases are characterized by CD16⁺, mature and inflammatory macrophages; some of which are in the process of maturation.

KEYWORDS

granuloma annulare, lupus miliaris disseminatus faciei, maturation, monocyte/macrophages, sarcoidosis

1 | INTRODUCTION

Peripheral blood monocytes are typically characterized as classical (CD14⁺⁺/CD16⁻), intermediate (CD14⁺/CD16⁺), or nonclassical (CD14⁻/CD16⁺⁺), according to their cell surface markers.¹ A simpler classification includes only classical (CD14⁺/CD16⁻) and nonclassical

(CD14⁺/CD16⁺ and CD14⁻/CD16⁺) subtypes, of which CD14⁺/CD16⁺ makes up about 10%.² Due to their inflammatory cytokine production and antigen-presenting ability, nonclassical monocytes are also termed inflammatory monocytes.

Previous studies have shown that CD14⁺⁺/CD16⁻ cells differentiate into CD14⁺/CD16⁺ macrophages.³ In addition, CD14⁺/CD16⁺

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2020 The Authors. Journal of Cutaneous Immunology and Allergy published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society for Cutaneous Immunology and Allergy

Cutaneous Immunology and Allergy

-WILEY 11

cells have high HLA-DR content and low levels of CD11b and CD33, which is consistent with the characteristics of alveolar tissue macrophages.³ CD16-positive tissue macrophages are the predominant effectors in granulomatous skin diseases; however, the distributions and levels of CD14 expression and CD16 expression in skin lesion monocytes/macrophages remain undetermined.

In the present study, we describe the maturation and immunological function of monocytes/macrophages in three granulomatous skin diseases—sarcoidosis, granuloma annulare (GA), and lupus miliaris disseminatus faciei (LMDF).

2 | METHODS

2.1 | Patients and specimens

Over the past 6 years, the Showa University Department of Dermatology (Tokyo, Japan) has diagnosed five cases of sarcoidosis, five cases of GA, and seven cases of LMDF. Thus, a total of 17 cases were retrospectively analyzed in this study. Ten sections from each patient's stored tissue block were included in our analysis. The study was approved by the ethics committee of Showa University. Immunohistochemistry was performed using a previously published amino acid polymer method (Nichirei).⁴ For antigen retrieval, paraffin-embedded sections were incubated at 98°C for 45 minutes in 1 mmol/L ethylenediaminetetraacetic acid (EDTA) and 10 mmol/L Tris-HCI buffer (pH 9.0). CD14 (Novocastra Laboratories Ltd; 1:100) and CD16 (Abcam; 1:100) primary antibodies were added to specimens and incubated overnight in a moist chamber at 4°C. The preparations were incubated with Simple Stain MAX-PO (Nichirei) for 30 minutes. Peroxidase binding sites were revealed using a Liquid DAB (3,3-diaminobenzidine tetrachloride) Plus Substrate Chromogen system (Dako), and sections were counterstained and mounted.

2.3 | Dual immunofluorescence labeling

Dual labeling of CD14/CD16, CD16/CD11c, CD16/CD68, and CD16/factor XIIIa (FXIIIa) were performed in sarcoidosis tissues (three cases), GA tissues (four cases), and LMDF tissues (three cases). Double labeling of CD16/CD56 was only performed for sarcoidosis



FIGURE 1 Immunohistochemical detection of CD14 and CD16. Low-power view of CD14 (A,C,E) labeling and CD16 (B,D,F) labeling shows a pattern consistent with granulomatous nodules in sarcoidosis (A,B), granuloma annulare (GA; C,D), and lupus miliaris disseminatus faciei (LMDF, E,F)

WILEY-

tissues (three cases). The deparaffinized sections were processed for antigen retrieval (described above). Primary antibodies included mouse anti-human CD14 antibody (Novocastra Laboratories Ltd; 1:100), rabbit anti-human CD16 antibody (Abcam; 1:100), mouse anti-human CD11c antibody (Novocastra Laboratories Ltd; 1:100), mouse anti-human CD68 antibody (Dako Japan; 1:150), mouse antihuman FXIIIa antibody (Novocastra Laboratories Ltd; 1:200), and mouse anti-human CD56 antibody (Novocastra Laboratories Ltd; 1:200), and mouse anti-human CD56 antibody (Novocastra Laboratories Ltd; 1:500). An Alexa Fluor[®] 594 F(ab7)2 fragment of goat anti-rabbit IgG [H+L] (Life Technologies) and an Alexa Fluor[®] 488 F(ab7)3 fragment of goat anti-mouse IgG [H+L] (Life Technologies) were used. The two signals were merged using the DP manager imaging software (Olympus).

3 | RESULTS

CD14 and CD16 immunohistochemical staining revealed patterns consistent with granulomatous nodules (Figure 1). Various types of multinucleated giant cells were observed across the disease types. The sarcoidosis series included three cases of CD14⁻/CD16⁺, one case of CD14⁺/CD16⁺, and one case of CD14⁺/CD16⁻ multinucleated

giant cells (Figure 2A,B and Table 1). The GA series included two cases of CD14⁻/CD16⁺ multinucleated giant cells (Figure 2C,D and Table 1). All seven LMDF samples contained CD16⁺ multinucleated giant cells; five CD14⁻/CD16⁺ and two CD14⁺/CD16⁺ (Figure 2E,F and Table 1).

Dual CD14 and CD16 labeling in GA tissues revealed low representation of CD14⁺/CD16⁻ cells in the outer granuloma nodule and a high CD16⁺ signal in the inner nodule (Figure 3A,B). In sarcoidosis tissues, CD14⁺/CD16⁺ cells (yellow) and CD14⁻/CD16⁺⁺ cells (red) predominated, whereas fewer CD14⁺/CD16⁻ cells (green) were observed. However, relative proportions of the three cell types varied across cases and nodules. Overall, green stains were most prevalent in granuloma nodule margins and occasionally scattered inside the nodules (Figure 4A).

Dual labeling of CD16 and other macrophage/dendritic cell markers (CD11c, CD68, FXIIIa, and CD56) revealed that there was an overlap between CD16⁺ cells (red) and CD68⁺ cells (green) in sarcoidosis tissues (Figure 4B). Most CD16⁺ cells (red) and CD11c⁺ cells (green) overlapped, but some CD16⁻/CD11c⁺ cells were also found along the granuloma margins (Figure 5A). There was no overlap between CD16⁺ cells (red) and FXIIIa⁺ cells (green) (Figure 5B). Previous studies reported that a CD56⁺ monocyte



FIGURE 2 Expression of CD14 and CD16 in multinucleated giant cells. Multinucleated giant cell expression of CD14⁻ (A,C,E) and CD16⁺ (B,D,F) (arrows). Sarcoidosis (A,B), GA (C,D), and LMDF (E,F)

subset was observed in this setting, but we found few $CD56^+$ cells in the sarcoid nodule and no obvious overlap with $CD16^+$ cells (data not shown).

In LMDF tissues, the nodule center was occupied by CD14⁻/ CD16⁺ cells (red) and surrounded by CD14⁺/CD16⁺ cells (yellow),

TABLE 1	Immunohistochemical analysis of CD14 and CD16 in			
granulomatous skin diseases				

		Granuloma		Multinucleated giant cell	
Case	Diagnosis	CD14	CD16	CD14	CD16
1	Sarcoidosis	(+)	(+)	(-)	(+)
2	Sarcoidosis	(+)	(+)	(+)	(-)
3	Sarcoidosis	(+)	(+)	(-)	(+)
4	Sarcoidosis	(+)	(+)	(+)	(+)
5	Sarcoidosis	(+)	(+)	(-)	(+)
1	GA	(+)	(+)	(-)	Not found
2	GA	(+)	(+)	(-)	(+)
3	GA	(+)	(+)	Not found	Not found
4	GA	(+)	(+)	Not found	Not found
5	GA	(+)	(+)	(-)	(+)
1	LMDF	(+)	(+)	(+)	(+)
2	LMDF	(+)	(+)	(-)	(+)
3	LMDF	(+)	(+)	(-)	(+)
4	LMDF	(+)	(+)	(+)	(+)
5	LMDF	(+)	(+)	(-)	(+)
6	LMDF	(+)	(+)	(-)	(+)
7	LMDF	(+)	(+)	(-)	(+)

Note: $CD14^{-}/CD16^{+}$ -multinucleated giant cells were detected in sarcoidosis (3/5 cases), GA (2/5 cases), and LMDF (5/7 cases) tissues.

-WILEY

with CD14⁺/CD16⁻ cells (green) distributed in the outermost layer (Figure 6A). CD16⁺ cells (red) and CD68⁺ cells (green) exhibited the highest degree of overlap. CD16⁻/CD68⁺ cells were distributed around the granulomas (Figure 6B). There was overlap between CD16⁺ and CD11c⁺ cells (yellow), but CD16⁺/CD11c⁻ (red) and CD16⁻/CD11c⁺ cells (green) were also found in some areas (Figure 7A). Similar to cases of sarcoidosis, there was no overlap between CD16⁺ (red) and FXIIIa⁺ cells (green) (Figure 7B).

4 | DISCUSSION/CONCLUSION

Our results show that, in cases of noninfectious cutaneous granulomatous disease, most infiltrating macrophages were CD14⁺/CD16⁺ and CD14⁻/CD16⁺⁺ mature macrophages. However, a small number of CD14⁺/CD16⁻ immature macrophages were identified at the periphery of granulomas in LMDF and GA tissues. These CD14⁺/CD16⁻ cells are derived from immature monocytes and migrate from the blood to the skin tissue.³ It is assumed that maturation continues during granuloma nodule formation, producing macrophages with strong CD16 expression. Compared with other peripheral blood monocytes, CD14⁺/ CD16⁺ monocytes produce high levels of TNF-a upon TLR-4 ligand stimulation with LPS and TLR-2 ligand stimulation with Pam3Cys.⁵ In addition, these cells express low mRNA and protein levels of the noninflammatory cytokine IL-10.6 Based on these observations, CD14⁺/ CD16⁺ cells can also be termed inflammatory monocytes. A report that examined the blood monocyte immune phenotype in sarcoidosis patients found that the percentage of CD14⁺/CD16⁺ monocytes increased significantly in sarcoidosis patients compared with healthy controls (11.8 \pm 4.9% vs 5.8 \pm 2.8%).⁷ In addition, a significant correlation was identified between serum angiotensin-converting enzyme levels and the proportion of CD14⁺/CD16⁺ monocytes in sarcoidosis patients.⁷ Based on these results, the authors suggested that CD14⁺/ CD16⁺ peripheral blood monocytes can be used as a sensitive marker



FIGURE 3 Dual immunofluorescence labeling of CD14/CD16 in GA tissue. CD14⁻/CD16⁺ cells (red) predominate in the inner portion of the granuloma, whereas a small proportion of CD14⁺/ CD16⁻ cells (green) are present within the outer portion



FIGURE 4 Dual immunofluorescence labeling of CD14/CD16 and CD16/CD68 in sarcoidosis tissue. A, CD14⁺/CD16⁺ (yellow) and CD14⁻/CD16⁺⁺ cells (red) occupy the majority of the granuloma, with CD14⁺/CD16⁻ cells (green) localized in a smaller area. B, Overlap of CD16⁺ (red) and CD68⁺ cells (green). The dotted line indicates the dermo-epidermal junction

FIGURE 5 Dual immunofluorescence labeling of CD16/CD11c and CD16/FXIIIa in sarcoidosis tissue. A, Most CD16⁺ (red) and CD11c⁺ cells (green) overlapped, but CD16⁻/CD11c⁺ cells were also found at the granuloma margins. B, No overlap between CD16⁺ (red) and FXIIIa⁺ cells (green) was observed. The dotted line indicates the dermo-epidermal junction

of disease activity in sarcoidosis.⁷ In the present study, we did not find a correlation between the proportion of $CD14^+/CD16^+$ macrophages and clinical activity, which may be due to the variation observed in the proportion and distribution of $CD14^+/CD16^-$ and $CD14^+/CD16^+$ cells across cases and nodules.

CD68, a 110-kDa membrane glycoprotein in the LAMP family, is widely expressed in monocytes/macrophages.⁸ We found the greatest overlap between the CD16 and CD68 signals. CD16 expression in dendritic cells (CD11c)⁹ was common but not universal. In addition, CD16 expression did not overlap with that of dermal dendritic cells derived from monocytes/macrophages or fibro-histiocytic cells (FXIIIa).¹⁰ Collectively, these results support the conclusion that the CD14⁺/CD16⁺ and CD14⁻/CD16⁺⁺ cells observed in our study are mature macrophages.

Multinucleated giant cells were found in four of five cases of sarcoidosis, two of five cases of GA, and all cases of LMDF. Multinucleated giant cells are formed in vitro from peripheral blood CD14⁺⁺/CD16⁻ monocytes via stimulation with cytokines and lectins.¹¹ IFN- γ plays an important role in monocyte fusion, but other cytokines such as IL-3, IL-4, IL-13, and GM-CSF are reported to be involved in multinucleated giant cell formation.¹¹ IFN- γ preferentially induces the development of Langhans-type giant cells, whereas IL-4 induces the development of foreign bodytype giant cells.¹² Relative to controls, peripheral blood monocytes from sarcoidosis patients better induced multinucleated giant cells in vitro due to their high expression of P2X7,¹³ a plasma membrane receptor responsible for cell-to-cell adhesion.¹¹ When concanavalin A was cultured with blood monocytes to examine **FIGURE 6** Dual immunofluorescence labeling of CD14/CD16 and CD16/ CD68 in LMDF tissue. A, CD14⁻/ CD16⁺ cells (red) occupied the center of the granulomatous nodules and were surrounded by CD14⁺/CD16⁺ cells (yellow). The outermost layer contained CD14⁺/CD16⁻ cells (green). B, Overlap of the CD16⁺ (red) and CD68⁺ cells (green). The dotted line indicates the dermoepidermal junction



FIGURE 7 Dual immunofluorescence labeling of CD16/CD11c and CD16/ FXIIIa in LMDF tissue. A, Positive overlap between CD16⁺ (orange) and CD11c⁺ (yellow) signals, and also between singlelabeled CD16⁺/CD11c⁻ cells (red) and CD16/CD11c⁺ cells (green). B, No overlap between CD16⁺ (red) and FXIIIa⁺ (green) signals was observed. The dotted line indicates the dermo-epidermal junction



giant cell formation, a fusion index of 30%-40% was obtained from freshly isolated monocytes and CD14⁺/CD16⁻ monocytes for both the Langhans type and foreign body types.¹⁴ However, CD14⁺/CD16⁺ monocytes did not undergo fusion,¹⁴ suggesting that CD14⁺/CD16⁻ monocytes were responsible for multinucleated giant cell formation. In the present evaluation of sarcoidosis tissue, CD14⁻/CD16⁺-multinucleated giant cells were observed in three cases, with each sample containing CD14⁺/CD16⁺ or CD14⁺/ CD16⁻-multinucleated giant cells. Thus, our findings suggest that sarcoidosis giant cells are formed via cell fusion of CD14⁺/CD16⁻ monocytes that are stimulated by cytokines, with these giant cells expressing CD16 in skin tissue upon further maturation. In only one case of sarcoidosis, CD14⁺/CD16⁻ immature giant cells were exceptionally observed. As for macrophages, the proportion of immature macrophages varies from case to case, and it is therefore assumed that giant cells can remain immature in the skin lesions. It is necessary to verify by increasing the number of cases.

LMDF is now recognized as a granulomatous reaction to the hair follicle and its contents.¹⁵ The LMDF central nodule exhibits evidence of necrosis and is negative for tuberculosis. The etiology of GA is diverse, but there is a degeneration of connective tissue in the central nodule, which is thought to result from an immunological response. In both LMDF and GA, mature CD14⁺/CD16⁺ macrophages accounted for the majority of granuloma cells, but a small proportion of CD14⁺/CD16⁻ cells were localized at the granuloma periphery. Thus, our results suggest that maturation progresses from the peripheral cells toward the center, where CD16 expression is stimulated. Cutaneous Immunology and Allergy

In summary, our evaluation indicates that the infiltrating cells in inflammatory granulomatous skin diseases are predominantly CD16⁺, mature, and inflammatory macrophages; some of which include residual CD14⁺/CD16⁻ immature macrophages that are in the process of maturation.

ACKNOWLEDGMENTS

WILEY-

We thank Textcheck for editing our English. The English in this document has been checked by at least two professional editors, both are native speakers of English. For certificate, please see: http://www. textcheck.com/certificate/iSvhYZ.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

DECLARATIONS

Protocol for this research project has been approved by a suitably constituted ethics committee of the institution and it conforms to the provisions of the Declaration of Helsinki. Ethics Committee on Research for Graduate School of Medicine, Showa University approval no. 1799. Since this study was a retrospective study, explanations and consents to patients were made by opting out on the Showa University website.

ORCID

Hirohiko Sueki Dhttps://orcid.org/0000-0001-5691-7211

REFERENCES

- 1. Passlick B, Flieger D, Ziegler-Heitbrock HWL. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989;74:2527–34.
- Ziegler-Heitbrock L. The CD14⁺ CD16⁺ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007;81:584–92.
- Ziegler-Heitbrock HWL, Fingerl G, Strobel M, Schraut W, Stelter F, Schutt C, et al. The novel subset of CD14⁺/CD16⁺ blood monocytes exhibits features of tissue macrophages. Eur J Immunol. 1993;23:2053–8.
- Hoshino Y, Nakata K, Hoshino S, Honda Y, Tse DB, Shioda T, et al. Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J Exp Med. 2002;195:495–505.

- Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, et al. The proinflammatory CD14⁺ CD16⁺ DR^{+ +} monocytes are a major source of TNF. J Immunol. 2002;168:3536-42.
- Mizuno K, Toma T, Tsukiji H, Okamoto H, Yamazaki H, Ohta K, et al. Selective expansion of CD16highCCR2-subpopulation of circulating monocytes with preferential production of haem oxygenase (HO)-1 in response to acute inflammation. Clin Exp Immunol. 2005;142:461–70.
- Okamoto H, Mizuno K, Horio T. Circulating CD14⁺ CD16⁺ monocytes are expanded in sarcoidosis patients. J Dermatol. 2003;30:503–9.
- Micklem K, Rigney E, Cordell J, Simmons D, Stross P, Turley H, et al. A human macrophage-associated antigen (CD68) detected by six different monoclonal antibodies. Br J Haematol. 1989;73:6–11.
- Blackford J, Reid HW, Pappin DJ, Bowers FS, Wilkinson JM. A monoclonal antibody, 3/22, to rabbit CD11c which induces homotypic T cell aggregation: evidence that ICAM-1 is a ligand for CD11c/CD18. Eur J Immunol. 1996;26:525–31.
- Sueki H, Whitaker D, Buchsbam M, Murphy GF. Novel interaction between dermal dendrocytes and mast cells in human skin. Implications for hemostasis and matrix repair. Lab Invest. 1993;69:160-72.
- 11. Okamoto H, Mizuno K, Horio T. Monocyte-derived multinucleated giant cells and sarcoidosis. J Dermatol Sci. 2003;31:119–28.
- NcNally AK, Anderson JM. Interleukin-4 induces foreign body giant cells from human monocyte/macrophages. Differential lymphokine regulation of macrophage fusion leads to morphological variants of multinucleated giant cells. Am J Pathol. 1995;147:1489–99.
- Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, Herren S, et al. Blockade of human P2X7 receptor function with a monoclonal antibody. Blood. 1998;92:3521–8.
- Mizuno K, Okamoto H, Horio T. Predominant induction of Langhans type multinucleated giant cells in vitro from human monocytes by muramyl dipeptide and the supernatant of concanavalin A-stimulated mononuclear cells. J Leukoc Biol. 2001;70:386–94.
- 15. Shitara A. Lupus miliaris disseminatus faciei. Int J Dermatol. 1984;23:542-4.

How to cite this article: Ito Y, Kitakawa M, Koshikawa S, Watanabe H, Sueki H. CD14 and CD16 expression in noninfectious granulomatous skin diseases. *J Cutan Immunol Allergy*. 2020;3:10–16. https://doi.org/10.1002/cia2.12091